Brain Tumor Research Center, Department of Neurological Surgery, University of California at San Francisco, California 94143, USA.
J Neurosurg. 2010 Aug;113(2):202-9. doi: 10.3171/2010.1.JNS091114.
Despite an increased understanding of the biology of malignant meningioma tumor progression, there is a paucity of published clinical data on factors affecting outcomes following treatment for these lesions. The authors present the largest case series to date dealing with these tumors, providing analysis of 63 patients.
The authors identified all patients undergoing resection of WHO Grade III tumors at their institution over a 16-year period. They analyzed clinical data from these patients, and performed Kaplan-Meier and Cox regression analyses to determine the impact of different clinical characteristics and different treatment modalities on survival following initial and repeat surgery for these lesions.
Sixty-three patients met inclusion criteria and were analyzed further. The median clinical follow-up time was 5 years (range 1-22 years). The 2-, 5-, and 10-year overall survival rates following initial operation were 82, 61, and 40%, respectively. Kaplan-Meier analysis demonstrated a marked survival benefit with repeat operation (53 vs 25 months, p = 0.02). Interestingly, patients treated with near-total resection experienced improved overall survival when compared with patients treated with gross-total resection at initial (p = 0.035) and repeat operations (p = 0.005). Twelve (19%) of 63 patients experienced significant neurological morbidity referable to the resection of their tumors.
Surgery is an effective treatment for WHO Grade III meningiomas at presentation and recurrence; however, aggressive attempts to achieve gross-total resection can be associated with significant neurological risk.
尽管人们对恶性脑膜瘤肿瘤进展的生物学有了更深入的了解,但关于影响这些病变治疗后结局的因素的临床数据却很少。作者报告了迄今为止最大的关于这些肿瘤的病例系列,对 63 例患者进行了分析。
作者在 16 年内确定了在其机构接受 III 级世界卫生组织肿瘤切除术的所有患者。他们分析了这些患者的临床数据,并进行了 Kaplan-Meier 和 Cox 回归分析,以确定不同的临床特征和不同的治疗方式对这些病变初次和再次手术后生存的影响。
63 例符合纳入标准的患者进一步被分析。中位临床随访时间为 5 年(范围 1-22 年)。初次手术后的 2 年、5 年和 10 年总生存率分别为 82%、61%和 40%。Kaplan-Meier 分析表明,再次手术具有明显的生存获益(53 个月 vs 25 个月,p=0.02)。有趣的是,与初次手术时行大体全切除的患者相比,行近全切除的患者在初次手术(p=0.035)和再次手术(p=0.005)时的总生存率均有显著提高。63 例患者中有 12 例(19%)因肿瘤切除而出现显著的神经功能缺损。
手术是治疗初发和复发的 III 级脑膜瘤的有效方法;然而,积极追求大体全切除可能会带来显著的神经风险。